Doxil (pegylated liposomal doxorubicin) is a drug approved for the treatment of ovarian, fallopian tube, and primary peritoneal cancers. However, the cancer may continue to grow despite this therapy.
In this study, researchers want to see if adding the drug Yondelis (trabectedin) to Doxil therapy is more effective than Doxil alone in women with ovarian, fallopian tube, or primary peritoneal cancers that have persisted or returned despite prior therapy. Yondelis is approved in Europe for the treatment of sarcoma, but its use in this study is considered investigational. It works by disrupting the DNA of cancer cells.
Patients will be randomly assigned to receive Doxil alone or Doxil plus Yondelis. Both drugs are given intravenously (by vein). Researchers will also study whether having a BRCA gene mutation influences how a patient responds to therapy.